Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9697-9710
Abstract
Objective: Idiopathic inflammatory myopathies (IIM) are classified into four subgroups: dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and sporadic inclusion body myositis (sIBM); however, the role of LGALS3BP in IIM remains unclear. Our study aimed to explore the ability of LGALS3BP to discriminate between the IIM subtypes. The correlation between serum LGALS3BP levels, clinical features, and inflammatory markers in patients with IIM was also assessed. Methods: Based on the Gene Expression Omnibus (GEO) database, we used bioinformatics analysis to screen for overlapping extracellular protein-differentially expressed genes between any two groups of DM, ASS, IMNM, and healthy controls (HCs). This study enrolled 84 patients with IIM and 36 HCs, and participant baseline data and laboratory parameters were recorded. Serum LGALS3BP levels were measured using an enzyme-linked immunosorbent assay (ELISA). Results: Through bioinformatics analysis, LGALS3BP was selected as a potential biomarker for the identification of DM, ASS, IMNM, and HC. LGALS3BP expression decreased sequentially in the DM, ASS, IMNM, and HC groups, with significant differences among the two groups. The ELISA results were similar to those of the bioinformatics analysis; however, the difference in serum LGALS3BP expression between DM and ASS was not statistically significant. According to the receiver operating characteristic (ROC) curve analysis, using HC as the control group, the area under the curve (AUC) values of serum LGALS3BP levels for the diagnosis of IIM, DM, and ASS were > 0.8. In addition, patients with elevated serum LGALS3BP levels had a higher prevalence of interstitial lung disease (ILD). Serum LGALS3BP levels correlated with inflammatory markers. Conclusion: LGALS3BP is differentially expressed in DM, ASS, IMNM, and HC and may assist in assessing the severity of IIM-ILD.Keywords
This publication has 43 references indexed in Scilit:
- Issues in the classification of myositis patients: an ongoing processClinical and Experimental Rheumatology, 2024
- 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD PatientsInternational Journal of Molecular Sciences, 2023
- Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositisRMD Open, 2023
- Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosusClinical and Experimental Rheumatology, 2021
- Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2020
- Reconstitution of Circulating Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation: Its Association with the Riboflavin Synthetic Pathway of Gut Microbiota in Cord Blood Transplant RecipientsThe Journal of Immunology, 2020
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial PneumoniasAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Magnetic Field Analysis of Lorentz Motors Using a Novel Segmented Magnetic Equivalent Circuit MethodSensors, 2013
- Biomineralization-based conversion of carbon dioxide to calcium carbonate using recombinant carbonic anhydraseChemosphere, 2012
- Identification of Human Melanoma Cellular and Secreted Ligands for Galectin-3Biochemical and Biophysical Research Communications, 1994